Connect with us

Hi, what are you looking for?

Jewish Business News


Perrigo good acquisition candidate for Teva – report

Bloomberg reports that increased competition with cheaper generics may push Teva to make a major acquisition soon.

Teva CEO Erez Vigodman

Perrigo Company (NYSE:PRGO; TASE:PRGO) may be a suitable acquisition for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), according to a report by “Bloomberg” today. According to the report’s authors, Teva will have to jump on the acquisition bandwagon soon, in part because of increased competition with cheaper generics companies – competition that will begin eroding Teva’s profits already this year.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Expiring patents and slowed growth are not unique to Teva, but while the Israeli pharmaceutical company did not make any significant acquisitions in 2014, acquisitions totaled $234 billion in pharmaceutical industry for the year globally.

Why Perrigo? The Bloomberg article explains that Teva plans to expand in the field of over-the-counter remedies (OTC), and Perrigo may be a good match. Another acquisition candidate mentioned in the article is Sweden’s Meda AB.

“Investors have seen what these deals are doing to the share prices” of other acquirers, Gabelli & Co. analyst Kevin Kedra told “Bloombers.” “Teva has a healthy business, but in this environment if you’re not doing deals, you’re probably not taking advantage of the opportunities that are out there.”

Last month, New York-based Royal Bank of Canada analyst Randall Stanicky wrote in a report that if Teva were to acquire Perrigo, it would boost Teva’s growth rate and reduce its exposure to Copaxone. Stanicky further estimated that a deal financed 80 percent with cash and 20% in stock would drive an increase of 30% in Teva’s share price.

Published by Globes [online], Israel business news –



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.